ZA975311B - Method of enhancing cognition - Google Patents

Method of enhancing cognition

Info

Publication number
ZA975311B
ZA975311B ZA975311A ZA975311A ZA975311B ZA 975311 B ZA975311 B ZA 975311B ZA 975311 A ZA975311 A ZA 975311A ZA 975311 A ZA975311 A ZA 975311A ZA 975311 B ZA975311 B ZA 975311B
Authority
ZA
South Africa
Prior art keywords
enhancing cognition
darifenacin
treatment
pharmaceutically acceptable
cognitive impairment
Prior art date
Application number
ZA975311A
Other languages
English (en)
Inventor
Michael John Allen
Brian Frank Johnson
Brian Robert Leaker
Robert Michael Wallis
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA975311B publication Critical patent/ZA975311B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
ZA975311A 1996-06-18 1997-06-17 Method of enhancing cognition ZA975311B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9612710.5A GB9612710D0 (en) 1996-06-18 1996-06-18 Method of treatment

Publications (1)

Publication Number Publication Date
ZA975311B true ZA975311B (en) 1998-12-17

Family

ID=10795468

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA975311A ZA975311B (en) 1996-06-18 1997-06-17 Method of enhancing cognition

Country Status (15)

Country Link
US (1) US5837724A (da)
EP (1) EP0813870B1 (da)
JP (1) JP3453493B2 (da)
KR (1) KR980000445A (da)
AT (1) ATE243514T1 (da)
AU (1) AU2495697A (da)
CA (1) CA2208111C (da)
DE (1) DE69722999T2 (da)
DK (1) DK0813870T3 (da)
ES (1) ES2197972T3 (da)
GB (1) GB9612710D0 (da)
HU (1) HUP9701060A3 (da)
IL (1) IL121036A0 (da)
PT (1) PT813870E (da)
ZA (1) ZA975311B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
MX344177B (es) 2008-03-27 2016-12-08 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
PL3061821T3 (pl) * 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
SG10202113198TA (en) * 2017-06-01 2021-12-30 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
BR112021005802B1 (pt) 2018-09-28 2022-02-15 Karuna Therapeutics, Inc Composição farmacêutica oral

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
JP3453493B2 (ja) 2003-10-06
JPH1059848A (ja) 1998-03-03
US5837724A (en) 1998-11-17
DE69722999T2 (de) 2003-12-18
AU2495697A (en) 1998-01-08
PT813870E (pt) 2003-10-31
IL121036A0 (en) 1997-11-20
DK0813870T3 (da) 2003-08-18
HU9701060D0 (en) 1997-08-28
CA2208111C (en) 2002-10-15
HUP9701060A3 (en) 1999-03-29
GB9612710D0 (en) 1996-08-21
HUP9701060A2 (hu) 1998-12-28
EP0813870B1 (en) 2003-06-25
CA2208111A1 (en) 1997-12-18
EP0813870A1 (en) 1997-12-29
ES2197972T3 (es) 2004-01-16
ATE243514T1 (de) 2003-07-15
KR980000445A (ko) 1998-03-30
DE69722999D1 (de) 2003-07-31

Similar Documents

Publication Publication Date Title
EP0711902A3 (en) Fracturing treatment with nitrogen and carbon dioxide in combination
GB9714544D0 (en) Treated titanium dioxide
HK1046274A1 (en) Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
PT936908E (pt) Derivados anticonvulsivos uteis no tratamento de esclerose lateral amiotrofica (ela)
HK1022270A1 (en) Use of anti-microtubule agents for treating or preventing multiple-sclerosis
BR9711530A (pt) Combina-Æo de terapia para tratamento de psicoses
EP0619983A3 (en) Surgical needle and device for grinding it.
PH31324A (en) Method of inhibiting imperfect tissue repair.
EP0672699A3 (en) Copolymers of 1,4-dioxepan-2-one and 1,5,8,12-tetraoxacyclotetracan-7-14-diode.
IL128379A0 (en) Treatment of the common cold or allergic rhinitis
ZA979731B (en) Treatment of asthma.
ZA97986B (en) Treatment of liquors.
ZA975311B (en) Method of enhancing cognition
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
AU1556497A (en) Agents for the treatment and prevention of aids
CA2347863A1 (en) Treatment of disorders of the outer retina
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
GR950100091A (en) Method for the treatment of plants.
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
ZA973843B (en) Treatment of asthma with TNFR-lg.
EP0888780A4 (en) COMPOSITION FOR TREATING CONTACT LENSES AND METHOD FOR USE THEREOF
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
HUP0102995A3 (en) Agents and method for the protective treatment of wood
ITTO940327A0 (it) Procedimento e dispositivo per l'addolcimento elettrolitico di pezzi d'acciaio.
EP0975265A4 (en) CURVED SURGICAL NEEDLE AND THEIR PRODUCTION PROCESS